Semaglutide vs Retatrutide
A comprehensive side-by-side comparison of Semaglutide and Retatrutide covering mechanisms, benefits, dosing, and safety.
Quick Verdict
Retatrutide is a triple agonist (GLP-1/GIP/glucagon) showing potentially greater weight loss than Semaglutide in early trials. However, Semaglutide has full FDA approval and extensive real-world data while Retatrutide is still in clinical development.
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the effects of the naturally occurring hormone GLP-1. It has gained significant attention for its powerful effects on appetite regulation and blood sugar control, leading to substantial weight loss in research subjects.
View Full ProfileRetatrutide
Retatrutide is the heavyweight champ of the incretin world right now. Eli Lilly engineered this 39-amino-acid peptide to hit three different receptors at once: GLP-1, GIP, and Glucagon. While semaglutide targets one pathway and tirzepatide hits two, retatrutide's 'triple G' approach pushed clinical trial weight loss past the 24% mark in under a year. We haven't seen anything this potent before outside of bariatric surgery.
View Full ProfileAt a Glance
Mechanism of Action
Semaglutide
Semaglutide activates GLP-1 receptors in the brain and pancreas. In the brain, it reduces appetite and increases satiety. In the pancreas, it enhances insulin secretion in a glucose-dependent manner while suppressing glucagon release.
Retatrutide
The GLP-1 and GIP agonism handles the standard incretin duties—crushing appetite, slowing gastric emptying, and sensitizing insulin. But the glucagon receptor agonism is the real party trick here. By stimulating the glucagon receptor, retatrutide actively increases your resting energy expenditure and rapidly oxidizes hepatic fat. You aren't just eating less; you are actively burning more fuel and clearing out a fatty liver.
Potential Benefits
Semaglutide
- + Significant weight loss
- + Reduced appetite
- + Improved blood sugar control
- + Cardiovascular benefits
- + Reduced food cravings
Retatrutide
- + Unprecedented fat mass reduction
- + Rapid clearance of hepatic steatosis (liver fat)
- + Sustained appetite suppression
- + Increased resting metabolic rate
- + Improved insulin sensitivity
Side Effects
Semaglutide
- ! Nausea (common initially)
- ! Vomiting
- ! Diarrhea
- ! Constipation
- ! Abdominal pain
Retatrutide
- ! Severe nausea if titrated too quickly
- ! Elevated resting heart rate (usually peaks around 24 weeks)
- ! Severe gastrointestinal distress (diarrhea or constipation)
- ! Significant lean tissue loss if subjects aren't resistance training
Research Areas
Semaglutide
Retatrutide
Frequently Asked Questions
Is Retatrutide better than Semaglutide?
Early clinical data suggests Retatrutide may produce greater weight loss than Semaglutide due to its triple-agonist mechanism. However, Retatrutide is still in clinical trials and lacks the extensive safety data that Semaglutide has accumulated over years of FDA-approved use.
When will Retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials. FDA approval timelines are uncertain, but it could potentially be available in the coming years if trials are successful. Semaglutide remains the established, approved option.
Related Comparisons
Explore These Peptides
Learn more about each peptide or find optimized stacking protocols.